• NEWS

Can mRNA vaccines transform the fight against Ebola?

On the heels of successful COVID-19 mRNA vaccines, the technology could hold promise in protecting against another deadly pathogen.
By
  1. Max Kozlov
    View author publications

    You can also search for this author in PubMed  Google Scholar

Access through your institution
Buy or subscribe

COVID-19 vaccines that rely on mRNA technology are credited with transforming humanity’s fight against the coronavirus pandemic. The vaccines — one made by drug giant Pfizer with German biotech firm BioNTech, another by US pharmaceutical company Moderna — sped through clinical trials in just months and gained approval from major regulatory bodies less than a year after development began. Now, as Uganda battles a type of Ebola without proven vaccines, is an mRNA vaccine against the deadly virus on the cards? And would such a vaccine similarly transform the fight against Ebola?

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 611, 439 (2022)

doi: https://doi.org/10.1038/d41586-022-03590-y

References

  1. Meyer, M. et al. J. Infect. Dis. 217, 451–455 (2018).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing